RECRO PHARMA INC (REPH) Stock Price, Quote, News and Overview
NASDAQ:REPH - Nasdaq - Common Stock
REPH Quote, Performance and Key Statistics
2.09
-0.01 (-0.48%)
The current stock price of REPH is 2.09 null. In the past month the price increased by 30.63%. In the past year, price decreased by -31.48%.
REPH Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 55.43 | 722.87B | ||
| JNJ | JOHNSON & JOHNSON | 14.9 | 360.41B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 20.38 | 327.79B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.93 | 228.66B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 15.9 | 216.88B | ||
| MRK | MERCK & CO. INC. | 10.15 | 198.52B | ||
| PFE | PFIZER INC | 7.47 | 136.28B | ||
| SNY | SANOFI-ADR | 10.68 | 116.48B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.38 | 95.36B | ||
| GSK | GSK PLC-SPON ADR | 8.61 | 77.15B | ||
| ZTS | ZOETIS INC | 26.11 | 69.97B | ||
| HLN | HALEON PLC-ADR | 21.24 | 46.84B |
Related stock screener links
About REPH
Company Profile
Recro Pharma, Inc. is a pharmaceutical company, which engages in the contract development and manufacturing organization (CDMO). The company is headquartered in Exton, Pennsylvania and currently employs 258 full-time employees. The company went IPO on 2014-03-07. The firm is engaged in solving formulation and manufacturing challenges for companies developing oral solid dose drug products. The company also focuses on developing sterile injectables oral liquids, tablets, topicals, liquid/powder filled capsules, ophthalmic droppers, liposomes and nano/microparticles. The company operates in one segment. The company provides support services capabilities, which includes preparation of clinical trial supplies, specialized services for the development and Good Manufacturing Practices (GMP) of products, as well as aseptic fill/finish and lyophilization. The firm develops and/or manufactures various products, such as Ritalin LA, Focalin XR, Verelan PM, Verelan SR, Verapamil PM and Verapamil SR. Its manufacturing and development capabilities include formulation, product development through clinical trial and commercial manufacturing, and specialized capabilities for solid oral dosage forms.
Company Info
RECRO PHARMA INC
1 E. Uwchlan Ave, Suite 112
Exton PENNSYLVANIA 19341 US
CEO: J. David Enloe
Employees: 258
Phone: 17705348239.0
RECRO PHARMA INC / REPH FAQ
What is the stock price of RECRO PHARMA INC today?
The current stock price of REPH is 2.09 null. The price decreased by -0.48% in the last trading session.
What is the ticker symbol for RECRO PHARMA INC stock?
The exchange symbol of RECRO PHARMA INC is REPH and it is listed on the Nasdaq exchange.
On which exchange is REPH stock listed?
REPH stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for RECRO PHARMA INC stock?
9 analysts have analysed REPH and the average price target is 5.1 null. This implies a price increase of 144.02% is expected in the next year compared to the current price of 2.09. Check the RECRO PHARMA INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is RECRO PHARMA INC worth?
RECRO PHARMA INC (REPH) has a market capitalization of 97.56M null. This makes REPH a Micro Cap stock.
How many employees does RECRO PHARMA INC have?
RECRO PHARMA INC (REPH) currently has 258 employees.
What are the support and resistance levels for RECRO PHARMA INC (REPH) stock?
RECRO PHARMA INC (REPH) has a support level at 1.65 and a resistance level at 2.11. Check the full technical report for a detailed analysis of REPH support and resistance levels.
Is RECRO PHARMA INC (REPH) expected to grow?
The Revenue of RECRO PHARMA INC (REPH) is expected to grow by 22.76% in the next year. Check the estimates tab for more information on the REPH EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy RECRO PHARMA INC (REPH) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of REPH, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of REPH, evaluating the profitability, health, valuation and growth aspects
- RECRO PHARMA INC (REPH) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- RECRO PHARMA INC (REPH) Sales and EPS estimates to see what analysts future expectations are.
- RECRO PHARMA INC (REPH) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- RECRO PHARMA INC (REPH) Insider and Institutional Ownership to learn about the owners and their transactions.
- RECRO PHARMA INC (REPH) Stock Chart to make your own analysis
- RECRO PHARMA INC (REPH) Latest news and press-releases to stay up to date.
Does RECRO PHARMA INC (REPH) stock pay dividends?
REPH does not pay a dividend.
When does RECRO PHARMA INC (REPH) report earnings?
RECRO PHARMA INC (REPH) will report earnings on 2022-05-04.
What is the Price/Earnings (PE) ratio of RECRO PHARMA INC (REPH)?
RECRO PHARMA INC (REPH) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.31).
REPH Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to REPH. When comparing the yearly performance of all stocks, REPH turns out to be only a medium performer in the overall market: it outperformed 67.27% of all stocks.
REPH Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to REPH. REPH has a medium profitability rating, but doesn't score so well on its financial health evaluation.
REPH Financial Highlights
Over the last trailing twelve months REPH reported a non-GAAP Earnings per Share(EPS) of -0.31. The EPS increased by 73.04% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -15.09% | ||
| ROA | -7.09% | ||
| ROE | N/A | ||
| Debt/Equity | 2.27 |
REPH Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 87% to REPH. The Buy consensus is the average rating of analysts ratings from 9 analysts.
For the next year, analysts expect an EPS growth of 5.68% and a revenue growth 22.76% for REPH